Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis
Frontiers in Pharmacology · 19.09.2023 · 14
DOI: 10.3389/fphar.2023.1269863 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.09.2023. Verfasst von Huanhuan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin University, Changchun, China. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Scientific and Technological Development Program, First Hospital of Jilin University.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 3% of new cancer cases and 3% of all deaths worldwide. Most HNSCC patients are locally advanced (LA) at diagnosis. The combination of radiotherapy (RT), chemotherapy, targeted therapy, and immunotherapy are the primary LA-HNSCC treatment options. Nevertheless, the choice of optimal LA-HNSCC treatment remains controversial. We systematically searched public databases for LA-HNSCC-related studies and assess treatment effectiveness and safety by assessing the objective response rate (ORR), ≥3 adverse events (AEs), overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), local-region control (LRC), and disease-specific survival (DSS). 126 randomized controlled clinical trials (RCTs) were included in this study. We show that concurrent RT with nimotuzumab or conventional concurrent chemo-radiotherapy (CCRT) had significantly better efficacy and long-term survival without increasing AEs than RT alone. Accelerated fractionated radiotherapy (AFRT) showed better efficiency than conventional fractionated RT, although it had higher AEs. In addition, concurrent cetuximab combined with RT failed to show a significant advantage over RT alone. Trial registration: PROSPERO CRD42022352127.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin University, Changchun, China.
- NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China.
- Division of Clinical Research, The First Hospital of Jilin University, Changchun, China.
- Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China.
- College of Basic Medical Sciences, Jilin University, Changchun, China.
Förderung
- Jilin Scientific and Technological Development Program
- First Hospital of Jilin University
Zitieren
APA
Wang, H., Zheng, Z., Zhang, Y., Bian, C., Bao, J., Xin, Y., & Jiang, X. (2023). Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1269863
Vancouver
Wang H, Zheng Z, Zhang Y, Bian C, Bao J, Xin Y, et al. Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1269863
BibTeX
@article{Wang2023,
author = {Wang, Huanhuan and Zheng, Zhuangzhuang and Zhang, Yangyu and Bian, Chenbin and Bao, Jindian and Xin, Ying and Jiang, Xin},
title = {Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1269863}
}
EUVIMED